Clinical Trials Interview June 2022

I think we should have a separate thread to unpack Roger's latest interview.

I think he was quite reluctant to make any bold statements, but he did provide a nod and a wink to the ultimate ambition which is success of MPL as a Human Cancer therapeutic. All along, that has been PAA's major goal, and if we can achieve our niche in the Human Cancer market, then shareholders will be reaping out-sized benefits.

My overall impression is that he was doing a balancing act - providing basic information to new investors while also attempting to bolster and re-assure existing shareholders.